OTC · Biotechnology

Lipella Pharmaceuticals Inc. (LIPO) Stock

$0.07 +0.00% OTC: LIPO Healthcare

Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies.

Valuation

MetricValue
Price$0.07
Market Cap$300354
P/E Ratio-0.05
P/B Ratio0.20
P/S Ratio0.30
EPS (TTM)$-4.79
52-Week High$0.82
52-Week Low$0.02
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-140.39%
ROA-165.46%
ROCE-231.85%
Gross Margin-500.00%
Operating Margin-500.00%
Net Margin-500.00%
Debt/Equity0.18
Current Ratio3.24

Annual Financials (USD)

Metric20202021202220232024
Revenue$1.0M$0$0$0$1.0M
Operating Profit$0$-2.0M$-3.0M$-5.0M$-5.0M
Net Profit$0$-2.0M$-3.0M$-5.0M$-5.0M
EPS$-0.23$-4.38$-5.12$-6.16$-4.79
Op Margin-5.9%-738.7%-1406.3%-1055.5%-947.2%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$1.0M$2.0M$6.0M$4.0M$3.0M
Total Liabilities$0$1.0M$1.0M$0$1.0M
Cash$1.0M$1.0M$5.0M$3.0M$2.0M
Borrowings$0$0$0$0$0

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$0$-1.0M$-2.0M$-3.0M$-4.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$1.0M$1.0M$4.0M$-2.0M$-1.0M
Free Cash Flow$0$-1.0M$-2.0M$-3.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.33
FCF Yield-785946.29%
Quick Ratio3.24
Interest Coverage0.00
Return 1Y-90.81%
Return 3Y-99.58%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTL $0.77 +1.96% -0.12 $1.80M 0.00%
AZTR $0.14 +0.80% -0.09 $1.49M 0.00%
DRMA $1.10 -0.90% -0.15 $749713 0.00%
GTBP $0.29 -4.65% -0.07 $3.12M 0.00%
INDP $1.39 -3.82% -0.06 $2.43M 0.00%

About Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.

Lipella Pharmaceuticals Inc. is headquartered in US.

Lipella Pharmaceuticals Inc. (LIPO) stock trades at $0.07 with a market capitalization of $300354. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of 0.20, price-to-sales of 0.30. Over the past 52 weeks the stock has ranged between $0.02 and $0.82, and currently trades 91.5% below its 52-week high.

On profitability, Lipella Pharmaceuticals Inc. generates a return on equity (ROE) of -140.39%, return on capital employed of -231.85%, an operating margin of -500.00%, a net profit margin of -500.00%.

Official website: www.lipella.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides